



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

May 25, 2018

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the board of directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Standalone audited financial results for the year ended on March 31, 2018 alongwith Auditor's Report.
2. Consolidated audited financial results for the year ended on March 31, 2018 alongwith Auditor's Report.
3. Declaration of Unmodified opinion on report issued by auditors of the Company M/s. Damania & Varaiya, Chartered Accountants on annual Standalone audited financial statement as well as annual Consolidated audited financial statement.

These financial results have been approved and taken on record by the board of directors at its meeting held today.


The meeting of the Board of Directors commenced at 12.00 noon and concluded at 2.58 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta

Company Secretary and Vice President - Compliance

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON 31ST MARCH, 2018

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017	31/03/2018	31/03/2017
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	31,883.52	30,474.20	30,626.19	125,473.42	119,869.42	141,351.20	136,831.70
2	Other Income	1,109.46	532.00	1,276.27	3,525.53	4,589.03	3,657.70	5,015.70
3	Total Income (1+2)	32,992.98	31,006.20	31,902.46	128,998.95	124,458.45	145,008.90	141,847.40
4	Expenses							
a.	Cost of materials consumed	11,771.17	10,081.54	9,131.39	38,701.68	36,709.36	38,701.68	36,709.36
b.	Purchases of stock-in-trade	727.51	2,279.03	2,857.52	9,304.46	9,624.47	15,739.56	15,244.24
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(159.59)	(1,676.13)	(663.24)	(38.81)	(1,805.26)	(659.41)	843.13
d.	Employee benefit expenses	5,538.30	5,310.67	4,989.62	21,730.93	18,786.11	25,109.87	21,734.16
e.	Finance Costs	95.12	61.07	(24.05)	341.36	500.13	349.21	537.16
f.	Depreciation and amortization expense	1,304.30	1,425.00	1,240.46	5,594.85	4,626.42	5,697.37	4,722.44
g.	Other Expenses	10,036.19	8,617.60	9,623.41	35,460.18	34,338.86	40,675.56	39,062.50
	Total Expenses (4)	29,313.00	26,098.78	27,155.11	111,094.65	102,780.09	125,613.84	118,852.99
5	Profit before Tax and share of joint venture (3-4)	3,679.98	4,907.42	4,747.35	17,904.30	21,678.36	19,395.06	22,994.41
6	Tax expenses	1,474.05	1,522.36	532.44	5,104.16	4,381.90	5,523.12	4,554.59
7	Net Profit/(Loss) after Tax before non controlling interest(5-6)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,871.94	18,439.82
8	Non controlling interest	-	-	-	-	-	37.85	33.55
9	Net Profit/(Loss) after Tax and non controlling interest (7-8)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,834.09	18,406.27
10	Other Comprehensive Income (net of Tax)	(147.84)	(13.10)	(246.21)	(241.63)	(270.43)	(39.36)	87.24
11	Total Comprehensive Income after Tax (9+10)	2,058.09	3,371.96	3,968.70	12,558.51	17,026.03	13,794.73	18,493.51
12	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	2.63	4.03	4.68	15.24	20.39	16.52	21.74
	(2) Diluted	2.63	4.03	4.68	15.24	20.39	16.52	21.74

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on May 25, 2018.
- The profit for the quarter ended March 31, 2018 was impacted by certain non-recurring operating expenses amounting to Rs. 949.76 lakhs. In addition, the profit for the year, was also impacted by higher staff cost due to sizeable increase in field force in domestic business, incremental tax due to GST, higher depreciation and strong Rupee during the year.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter and year ended March 31, 2018 are not comparable with the previous corresponding periods as the figures for those periods were inclusive of excise duty.
- The Board of Directors has recommended a dividend of Rs. 2 per equity share of face value of Rs. 2 (100%).
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2017-18.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2018 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at Mar 31, 2018	As at Mar 31, 2017	As at Mar 31, 2018	As at Mar 31, 2017
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	55,993.76	59,366.61	56,371.11	59,727.03
(b) Capital work-in-progress	1,740.23	376.25	1,740.23	376.25
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	997.01	1,502.41	2,265.23	2,903.40
(e) Financial Assets				
(i) Investments	18,292.47	31,880.88	4,995.79	18,584.20
(ii) Trade receivables	-	-	-	-
(iii) Loans	332.67	328.94	332.67	328.94
(iv) Others	344.10	350.26	344.10	350.26
(f) Other non-current assets	426.08	330.76	426.08	330.76
TOTAL non current assets	78,126.32	94,136.11	71,789.21	87,914.84

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Chenergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com


CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Particulars	Standalone		Consolidated	
	As at Mar 31,2018	As at Mar 31,2017	As at Mar 31,2018	As at Mar 31,2017
(II) Current assets				
(a) Inventories	17,581.44	15,995.57	21,373.14	20,016.86
(b) Financial Assets				
(i) Investments	38,376.60	22,496.16	38,376.60	22,496.16
(ii) Trade receivables	30,054.05	26,509.52	30,072.96	26,596.62
(iii) Cash and cash equivalents	1,495.33	719.71	2,992.32	1,338.65
(iv) Loans	20.60	44.32	87.91	92.61
(v) Others	73.83	73.91	79.27	78.98
(c) Current Tax Assets (Net)	806.28	-	829.46	-
(c) Other current assets	10,131.15	8,461.97	10,888.12	8,869.14
TOTAL current assets	98,539.28	74,301.16	104,699.78	79,489.02
Total Assets	176,665.60	168,437.27	176,488.99	167,403.86
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,671.40	1,696.40	1,671.40	1,696.40
(b) Other Equity	143,667.41	137,089.73	142,484.40	134,670.50
(c) non controlling interest			277.18	218.05
Total Equity	145,338.81	138,786.13	144,432.98	136,584.95
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	967.36	888.01	967.36	1,256.20
(b) Deferred tax liabilities (Net)	4,970.15	2,895.35	3,238.58	1,046.39
(c) Other non-current liabilities	360.01	395.48	360.01	395.48
TOTAL non current Liabilities	6,297.52	4,178.84	4,565.95	2,698.07
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,847.62	4,886.03	2,929.28	4,886.03
(ii) Trade payables	10,022.10	7,903.47	11,039.50	9,897.71
(iii) Other financial liabilities	10,119.56	10,977.95	10,793.35	11,376.26
(b) Other current liabilities	1,148.76	830.07	1,160.14	838.44
(c) Provisions	891.23	787.39	1,552.50	1,035.01
(d) Current Tax Liabilities (Net)	-	87.39	15.29	87.39
TOTAL Current Liabilities	25,029.27	25,472.30	27,490.06	28,120.84
Total Equity and Liabilities	176,665.60	168,437.27	176,488.99	167,403.86

For J.B. Chemicals & Pharmaceuticals Ltd.


J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 25/05/2018





Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com


CIN: L24390MH1976PLC019380

Independents Auditors' Report on Quarter and Annual Standalone Financial Results of the J. B. Chemicals and Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
J. B. Chemicals and Pharmaceuticals Limited

1. We have audited the accompanying Statement of Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited ('the Company'), for the Quarter and year ended March 31, 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initialed by us for the purpose of identification.
2. This Statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on May 25, 2018. The Statement, as it relates to the quarter ended March 31, 2018, has been compiled from the related interim standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2018, has been compiled from the related annual standalone financial statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such interim standalone financial statements and annual standalone financial statements.
3. We conducted our audits in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016; and
 - ii. give a true and fair view in conformity with the aforesaid Ind AS and Other Accounting principles generally accepted in India of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended 31 March 2018.
5. The Statement includes the results for the Quarter ended March 31, 2018, being the balancing figure between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Other Matter:

The comparative figures for the quarter and year ended March, 2017 prepared in accordance with applicable Indian Accounting Standards ('Ind AS') were audited by the erstwhile auditors who had expressed unmodified audit opinion on these financial results/ financial statements vide their reports dated May 23, 2017.

For Damania & Varaiya

Chartered Accountants

Firm Registration No. 102079W

CA Bharat Jain

Partner

Membership No: 100583



Place: Mumbai

Date : May 25, 2018.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON 31ST MARCH, 2018

(Rs. in lakhs)


Sl. No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017	31/03/2018	31/03/2017
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	31,883.52	30,474.20	30,626.19	125,473.42	119,869.42	141,351.20	136,831.70
2	Other Income	1,109.46	532.00	1,276.27	3,525.53	4,589.03	3,657.70	5,015.70
3	Total Income (1+2)	32,992.98	31,006.20	31,902.46	128,998.95	124,458.45	145,008.90	141,847.40
4	Expenses							
a.	Cost of materials consumed	11,771.17	10,081.54	9,131.39	38,701.68	36,709.36	38,701.68	36,709.36
b.	Purchases of stock-in-trade	727.51	2,279.03	2,857.52	9,304.46	9,624.47	15,739.56	15,244.24
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(159.59)	(1,676.13)	(663.24)	(38.81)	(1,805.26)	(659.41)	843.13
d.	Employee benefit expenses	5,538.30	5,310.67	4,989.62	21,730.93	18,786.11	25,109.87	21,734.16
e.	Finance Costs	95.12	61.07	(24.05)	341.36	500.13	349.21	537.16
f.	Depreciation and amortization expense	1,304.30	1,425.00	1,240.46	5,594.85	4,626.42	5,697.37	4,722.44
g.	Other Expenses	10,036.19	8,617.60	9,623.41	35,460.18	34,338.86	40,675.56	39,062.50
	Total Expenses (4)	29,313.00	26,098.78	27,155.11	111,094.65	102,780.09	125,613.84	118,852.99
5	Profit before Tax and share of joint venture (3-4)	3,679.98	4,907.42	4,747.35	17,904.30	21,678.36	19,395.06	22,994.41
6	Tax expenses	1,474.05	1,522.36	532.44	5,104.16	4,381.90	5,523.12	4,554.59
7	Net Profit/(Loss) after Tax before non controlling interest(5-6)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,871.94	18,439.82
8	Non controlling interest	-	-	-	-	-	37.85	33.55
9	Net Profit/(Loss) after Tax and non controlling interest (7-8)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,834.09	18,406.27
10	Other Comprehensive Income (net of Tax)	(147.84)	(13.10)	(246.21)	(241.63)	(270.43)	(39.36)	87.24
11	Total Comprehensive Income after Tax (9+10)	2,058.09	3,371.96	3,968.70	12,558.51	17,026.03	13,794.73	18,493.51
12	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
(1)	Basic	2.63	4.03	4.68	15.24	20.39	16.52	21.74
(2)	Diluted	2.63	4.03	4.68	15.24	20.39	16.52	21.74

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on May 25, 2018.
- The profit for the quarter ended March 31, 2018 was impacted by certain non-recurring operating expenses amounting to Rs. 949.76 lakhs. In addition, the profit for the year, was also impacted by higher staff cost due to sizeable increase in field force in domestic business, incremental tax due to GST, higher depreciation and strong Rupee during the year.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter and year ended March 31, 2018 are not comparable with the previous corresponding periods as the figures for those periods were inclusive of excise duty.
- The Board of Directors has recommended a dividend of Rs. 2 per equity share of face value of Rs. 2 (100%).
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2017-18.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2018 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at Mar 31, 2018	As at Mar 31, 2017	As at Mar 31, 2018	As at Mar 31, 2017
ASSETS				
(i) Non-current assets				
(a) Property, Plant and Equipment	55,993.76	59,366.61	56,371.11	59,727.03
(b) Capital work-in-progress	1,740.23	376.25	1,740.23	376.25
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	997.01	1,502.41	2,265.23	2,903.40
(e) Financial Assets				
(i) Investments	18,292.47	31,880.88	4,995.79	18,584.20
(ii) Trade receivables	-	-	-	-
(iii) Loans	332.67	328.94	332.67	328.94
(iv) Others	344.10	350.26	344.10	350.26
(f) Other non-current assets	426.08	330.76	426.08	330.76
TOTAL non-current assets	78,126.32	94,136.11	71,789.21	87,914.84



Registered Office:
Nandam Centre, B Wing, 4th Floor
Hind. Co. Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Particulars	Standalone		Consolidated	
	As at Mar 31,2018	As at Mar 31,2017	As at Mar 31,2018	As at Mar 31,2017
(II) Current assets				
(a) Inventories				
(b) Financial Assets	17,581.44	15,995.57	21,373.14	20,016.86
(i) Investments				
(ii) Trade receivables	38,376.60	22,496.16	38,376.60	22,496.16
(iii) Cash and cash equivalents	30,054.05	26,509.52	30,072.96	26,596.62
(iv) Loans	1,495.33	719.71	2,992.32	1,338.65
(v) Others	20.60	44.32	87.91	92.61
(c) Current Tax Assets (Net)	73.83	73.91	79.27	78.98
(c) Other current assets	806.28	-	829.46	-
TOTAL current assets	10,131.15	8,461.97	10,888.12	8,869.14
Total Assets	98,539.28	74,301.16	104,699.78	79,489.02
EQUITY AND LIABILITIES	176,665.60	168,437.27	176,488.99	167,403.86
Equity				
(a) Equity Share capital	1,671.40	1,696.40	1,671.40	1,696.40
(b) Other Equity	143,667.41	137,089.73	142,484.40	134,670.50
(c) non controlling interest			277.18	218.05
Total Equity	145,338.81	138,786.13	144,432.98	136,584.95
LIABILITIES	145,338.81	138,786.13	144,432.98	136,584.95
(I) Non-current liabilities				
(a) Provisions				
(b) Deferred tax liabilities (Net)	967.36	888.01	967.36	1,256.20
(c) Other non-current liabilities	4,970.15	2,895.35	3,238.58	1,046.39
TOTAL non current Liabilities	360.01	395.48	360.01	395.48
(II) Current liabilities	6,297.52	4,178.84	4,565.95	2,698.07
(a) Financial Liabilities				
(i) Borrowings				
(ii) Trade payables	2,847.62	4,886.03	2,929.28	4,886.03
(iii) Other financial liabilities	10,022.10	7,903.47	11,039.50	9,897.71
(b) Other current liabilities	10,119.56	10,977.95	10,793.35	11,376.26
(c) Provisions	1,148.76	830.07	1,160.14	838.44
(d) Current Tax Liabilities (Net)	891.23	787.39	1,552.50	1,035.01
TOTAL Current Liabilities	25,029.27	25,472.30	27,490.06	28,120.84
Total Equity and Liabilities	176,665.60	168,437.27	176,488.99	167,403.86

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
J.B. Mody

Chairman & Managing Director



Place : Mumbai
Date : 25/05/2018

Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380


Independent Auditors' Report on the Annual Consolidated Financial Results of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited

1. We have audited the accompanying Statement of Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and Its subsidiaries together referred to as ("the JBCPL Group")), for the year ended 31st March, 2018 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initialed by us for the purpose of identification.
2. This Statement, which is the responsibility of the Holding Company's Management and has been reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on May 25, 2018, has been compiled from the related annual consolidated financial statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of annual consolidated financial statements.
3. We conducted our audits in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in the paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated Ind AS financial statements.



4. In Our opinion and to the best of our information and according to the explanations given to us, consideration of the reports of the other auditors on separate financial statements / consolidated financial statement and the other financial information of subsidiaries referred to in paragraph below, the Statement:

Includes the year to date financial results of the following subsidiaries:

a) List of Subsidiaries:

- i. 000 Unique Pharmaceutical Laboratories,
- ii. Unique Pharmaceutical Laboratories FZE and
- iii. Biotech Laboratories (Pty.) Ltd (Subsidiary of Unique Pharmaceutical Laboratories FZE)

b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and

c) give a true and fair view in conformity with the aforesaid Ind AS and other accounting principles generally accepted in India of the consolidated profit, total comprehensive Income and other financial information of the JBCPL Group for the year ended 31st March, 2018.

5. We did not audit the financial statements / financial information of the subsidiaries referred in paragraph 4 (a) above included in the consolidated year to date results, whose financial statements reflect total assets of Rs 26,569.45 Lakhs as at 31st March, 2018, as well as the total revenue of Rs 29,154.00 Lakhs for the year ended on that date. These financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the year to date consolidated financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors.

Our opinion is not modified in respect of above matters with regards to our reliance on the work done and the reports of the other auditors.


Other Matter:


The comparative figures for the year ended March, 2017 prepared in accordance with applicable Indian Accounting Standards ('Ind AS') were audited by the erstwhile auditors who had expressed unmodified audit opinion on these financial statements vide their reports dated May 23, 2017.

For Damania & Varaiya

Chartered Accountants

Firm Registration No. 102079W


CA Bharat Jain
Partner
Membership No: 100583



Place: Mumbai

Date : May 25, 2018.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED


STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON 31ST MARCH, 2018

		(Rs. in lakhs)							
Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended		
		31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017	31/03/2018	31/03/2017	
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	
1	Revenue from Operations	31,883.52	30,474.20	30,626.19	125,473.42	119,869.42	141,351.20	136,831.70	
2	Other Income	1,109.46	532.00	1,276.27	3,525.53	4,589.03	3,657.70	5,015.70	
3	Total Income (1+2)	32,992.98	31,006.20	31,902.46	128,998.95	124,458.45	145,008.90	141,847.40	
4	Expenses								
	a. Cost of materials consumed	11,771.17	10,081.54	9,131.39	38,701.68	36,709.36	38,701.68	36,709.36	
	b. Purchases of stock-in-trade	727.51	2,279.03	2,857.52	9,304.46	9,624.47	15,739.56	15,244.24	
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(159.59)	(1,676.13)	(663.24)	(38.81)	(1,805.26)	(659.41)	843.13	
	d. Employee benefit expenses	5,538.30	5,310.67	4,989.62	21,730.93	18,786.11	25,109.87	21,734.16	
	e. Finance Costs	95.12	61.07	(24.05)	341.36	500.13	349.21	537.16	
	f. Depreciation and amortization expense	1,304.30	1,425.00	1,240.46	5,594.85	4,626.42	5,697.37	4,722.44	
	g. Other Expenses	10,036.19	8,617.60	9,623.41	35,460.18	34,338.86	40,675.56	39,062.50	
	Total Expenses (4)	29,313.00	26,098.78	27,155.11	111,094.65	102,780.09	125,613.84	118,852.99	
5	Profit before Tax and share of joint venture (3-4)	3,679.98	4,907.42	4,747.35	17,904.30	21,678.36	19,395.06	22,994.41	
6	Tax expenses	1,474.05	1,522.36	532.44	5,104.16	4,381.90	5,523.12	4,554.59	
7	Net Profit/(Loss) after Tax before non controlling interest(5-6)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,871.94	18,439.82	
8	Non controlling interest	-	-	-	-	-	37.85	33.55	
9	Net Profit/(Loss) after Tax and non controlling interest (7-8)	2,205.93	3,385.06	4,214.91	12,800.14	17,296.46	13,834.09	18,406.27	
10	Other Comprehensive Income (net of Tax)	(147.84)	(13.10)	(246.21)	(241.63)	(270.43)	(39.36)	87.24	
11	Total Comprehensive Income after Tax (9+10)	2,058.09	3,371.96	3,968.70	12,558.51	17,026.03	13,794.73	18,493.51	
12	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)								
	(1) Basic	2.63	4.03	4.68	15.24	20.39	16.52	21.74	
	(2) Diluted	2.63	4.03	4.68	15.24	20.39	16.52	21.74	

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on May 25, 2018.
- The profit for the quarter ended March 31, 2018 was impacted by certain non-recurring operating expenses amounting to Rs. 949.76 lakhs. In addition, the profit for the year, was also impacted by higher staff cost due to sizeable increase in field force in domestic business, incremental tax due to GST, higher depreciation and strong Rupee during the year.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter and year ended March 31, 2018 are not comparable with the previous corresponding periods as the figures for those periods were inclusive of excise duty.
- The Board of Directors has recommended a dividend of Rs. 2 per equity share of face value of Rs. 2 (100%).
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2017-18.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2018 is as under:

Particulars	(Rs. in lakhs)			
	Standalone		Consolidated	
	As at Mar 31, 2018	As at Mar 31, 2017	As at Mar 31, 2018	As at Mar 31, 2017
ASSETS				
(i) Non-current assets				
(a) Property, Plant and Equipment	55,993.76	59,366.61	56,371.11	59,727.03
(b) Capital work-in-progress	1,740.23	376.25	1,740.23	376.25
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	997.01	1,502.41	2,265.23	2,903.40
(e) Financial Assets				
(i) Investments	18,292.47	31,880.88	4,995.79	18,584.20
(ii) Trade receivables	-	-	-	-
(ii) Loans	332.67	328.94	332.67	328.94
(iv) Others	344.10	350.26	344.10	350.26
(f) Other non-current assets	426.08	330.76	426.08	330.76
TOTAL non current assets	78,126.32	94,136.11	71,789.21	87,914.84



Registered Office:

Neelam Centre, B Wing, 4th Floor

And Cycle Road, Worli

Mumbai - 400 030

Corporate Office:

Energy IT Park

Unit A2, 3rd Floor, Unit A, 8th Floor

Appa Saheb Marathe Marg, Prabhadevi

Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380




J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Particulars	Standalone		Consolidated	
	As at Mar 31, 2018	As at Mar 31, 2017	As at Mar 31, 2018	As at Mar 31, 2017
(ii) Current assets				
(a) Inventories	17,581.44	15,995.57	21,373.14	20,016.86
(b) Financial Assets				
(i) Investments	38,376.60	22,496.16	38,376.60	22,496.16
(ii) Trade receivables	30,054.05	26,509.52	30,072.96	26,596.62
(iii) Cash and cash equivalents	1,495.33	719.71	2,992.32	1,338.65
(iv) Loans	20.60	44.32	87.91	92.61
(v) Others	73.83	73.91	79.27	78.98
(c) Current Tax Assets (Net)	806.28	-	829.46	-
(c) Other current assets	10,131.15	8,461.97	10,888.12	8,869.14
TOTAL current assets	98,539.28	74,301.16	104,699.78	79,489.02
Total Assets	176,665.60	168,437.27	176,488.99	167,403.86
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,671.40	1,696.40	1,671.40	1,696.40
(b) Other Equity	143,667.41	137,089.73	142,484.40	134,670.50
(c) non controlling interest			277.18	218.05
Total Equity	145,338.81	138,786.13	144,432.98	136,584.95
LIABILITIES				
(i) Non-current liabilities				
(a) Provisions	967.36	888.01	967.36	1,256.20
(b) Deferred tax liabilities (Net)	4,970.15	2,895.35	3,238.58	1,046.39
(c) Other non-current liabilities	360.01	395.48	360.01	395.48
TOTAL non current Liabilities	6,297.52	4,178.84	4,565.95	2,698.07
(ii) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,847.62	4,886.03	2,929.28	4,886.03
(ii) Trade payables	10,022.10	7,903.47	11,039.50	9,897.71
(iii) Other financial liabilities	10,119.56	10,977.95	10,793.35	11,376.26
(b) Other current liabilities	1,148.76	830.07	1,160.14	838.44
(c) Provisions	891.23	787.39	1,552.50	1,035.01
(d) Current Tax Liabilities (Net)	-	87.39	15.29	87.39
TOTAL Current Liabilities	25,029.27	25,472.30	27,490.06	28,120.84
Total Equity and Liabilities	176,665.60	168,437.27	176,488.99	167,403.86

For J.B. Chemicals & Pharmaceuticals Ltd.

J. B. Mody
J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 25/05/2018



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

May 25, 2018

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Declaration pursuant to SEBI notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 read with circular CIR/CFD/CMD/56/2016 dated May 27, 2016.

This is to inform you that auditors of the Company M/s. Damania & Varaiya, Chartered Accountants, have issued their report on annual Standalone audited financial statement as well as annual Consolidated audited financial statement, for the year ended March 31, 2018.

We hereby state & declare that the above two audit report have been issued with unmodified opinion.

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary and Vice President - Compliance

📍 **Registered Office:**

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**

Chenergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380